EGFR and glioblastoma: Low doses of DOX were safe for patients, even with extended (>6 weeks) dosing [95], and showed promising results in a phase I trial (GBM-LIPO trial) in which patients with relapsed glioblastoma harboring an EGFR amplification were treated with anti-EGFR doxorubicin-loaded immunoliposomes (anti-EGFR ILs-DOX) [46].